Global Pediatric Neuroblastoma Treatment Market is valued at approximately XX in 2021 and is anticipated to grow with a healthy growth rate of more than 6% over the forecast period 2022-2028. The most common type of extracranial solid tumour in children is neuroblastoma. The rising prevalence of neuroblastoma in children, as well as increased research and development and increased awareness of available cancer treatments, are all contributing to the market's growth. Neuroblastoma is estimated to affect one out of every 7,000 live births, according to a National Cancer Institute article published in February 2022. In children under the age of 15, the annual incidence is 10.54 cases per 1 million. Around 37% of patients are diagnosed as infants, and 90% are under the age of 5, with a median age of 19 months at diagnosis. Furthermore, the government's increasing investments in research and development programmes to develop the medical infrastructure in the paediatric section, as well as increased awareness of paediatric neuroblastoma treatment, are boosting the market growth. Furthermore, increasing investments in evaluating the efficacy of chemotherapy in paediatric neuroblastoma will propel the market forward. For example, in January 2022, Jason Shohet, MD, PhD, was awarded a new two-year USD 300,000 Scholar Hope Grant to focus on drug resistance in neuroblastoma chemotherapy treatments. It is a cancer of the peripheral nervous system that is fatal in children. However, the high cost of paediatric neuroblastoma treatment is a significant impediment to market expansion.
The key regions considered for the global Pediatric Neuroblastoma Treatment market study include: Asia Pacific, North America, Europe, Latin America, and Rest of the World. Throughout the forecast period, North America is expected to dominate the overall market. The high prevalence of paediatric neuroblastoma in the region, as well as established healthcare infrastructure, are some of the key factors responsible for the region's large market share. Additionally, favourable government initiatives and an increase in the number of research partnerships are expected to drive market growth. The Asia Pacific (APAC) region, on the other hand, will grow at a steady pace over the forecast period. Increased public investment and improvements in healthcare infrastructure will be attributed to this growth.
Major market players included in this report are:
- United Therapeutics Corporation
- APEIRON Biologics AG
- Baxter International
- Pfizer, Inc.
- Bayer AG
- MacroGenics, Inc.
- Sartorius AG
- CELLECTAR BIOSCIENCES, INC.
- PROVECTUS BIOPHARMACEUTICALS, INC.
- Y-mAbs Therapeutics, Inc.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Treatment Type:
- Chemotherapy
- Immunotherapy
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
By Region:
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
Furthermore, years considered for the study are as follows:
- Historical year - 2018, 2019, 2020
- Base year - 2021
- Forecast period - 2022 to 2028
Target Audience of the Global Pediatric Neuroblastoma Treatment Market in Market Study:
- Key Consulting Companies & Advisors
- Large, medium-sized, and small enterprises
- Venture capitalists
- Value-Added Resellers (VARs)
- Third-party knowledge providers
- Investment bankers
- Investors
Table of Contents
Chapter 1. Executive Summary
- 1.1. Market Snapshot
- 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2028 (USD Billion)
- 1.2.1. Pediatric Neuroblastoma Treatment Market, by Region, 2020-2028 (USD Billion)
- 1.2.2. Pediatric Neuroblastoma Treatment Market, by Treatment Type, 2020-2028 (USD Billion)
- 1.2.3. Pediatric Neuroblastoma Treatment Market, by Distribution Channel, 2020-2028 (USD Billion)
- 1.3. Key Trends
- 1.4. Estimation Methodology
- 1.5. Research Assumption
Chapter 2. Global Pediatric Neuroblastoma Treatment Market Definition and Scope
- 2.1. Objective of the Study
- 2.2. Market Definition & Scope
- 2.2.1. Scope of the Study
- 2.2.2. Industry Evolution
- 2.3. Years Considered for the Study
- 2.4. Currency Conversion Rates
Chapter 3. Global Pediatric Neuroblastoma Treatment Market Dynamics
- 3.1. Pediatric Neuroblastoma Treatment Market Impact Analysis (2020-2028)
- 3.1.1. Market Drivers
- 3.1.1.1. Increasing burden of pediatric neuroblastoma coupled with increasing R&D
- 3.1.1.2. Rise in awareness of available treatment for cancer
- 3.1.2. Market Challenges
- 3.1.2.1. High cost and side effects associated with cancer therapy
- 3.1.3. Market Opportunities
- 3.1.3.1. Intensive research and development
Chapter 4. Global Pediatric Neuroblastoma Treatment Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model (2018-2028)
- 4.2. PEST Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.3. Investment Adoption Model
- 4.4. Analyst Recommendation & Conclusion
- 4.5. Top investment opportunity
- 4.6. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
- 5.1.1. Assessment of the overall impact of COVID-19 on the industry
- 5.1.2. Pre COVID-19 and post COVID-19 Market scenario
Chapter 6. Global Pediatric Neuroblastoma Treatment Market, by Treatment Type
- 6.1. Market Snapshot
- 6.2. Global Pediatric Neuroblastoma Treatment Market by Treatment Type, Performance - Potential Analysis
- 6.3. Global Pediatric Neuroblastoma Treatment Market Estimates & Forecasts by Treatment Type, 2018-2028 (USD Billion)
- 6.4. Pediatric Neuroblastoma Treatment Market, Sub Segment Analysis
- 6.4.1. Chemotherapy
- 6.4.2. Immunotherapy
- 6.4.3. Others
Chapter 7. Global Pediatric Neuroblastoma Treatment Market, by Distribution Channel
- 7.1. Market Snapshot
- 7.2. Global Pediatric Neuroblastoma Treatment Market by Distribution Channel, Performance - Potential Analysis
- 7.3. Global Pediatric Neuroblastoma Treatment Market Estimates & Forecasts by Distribution Channel, 2018-2028 (USD Billion)
- 7.4. Pediatric Neuroblastoma Treatment Market, Sub Segment Analysis
- 7.4.1. Hospital Pharmacies
- 7.4.2. Retail Pharmacies
Chapter 8. Global Pediatric Neuroblastoma Treatment Market, Regional Analysis
- 8.1. Pediatric Neuroblastoma Treatment Market, Regional Market Snapshot
- 8.2. North America Pediatric Neuroblastoma Treatment Market
- 8.2.1. U.S. Pediatric Neuroblastoma Treatment Market
- 8.2.1.1. Treatment Type breakdown estimates & forecasts, 2018-2028
- 8.2.1.2. Distribution Channel breakdown estimates & forecasts, 2018-2028
- 8.2.2. Canada Pediatric Neuroblastoma Treatment Market
- 8.3. Europe Pediatric Neuroblastoma Treatment Market Snapshot
- 8.3.1. U.K. Pediatric Neuroblastoma Treatment Market
- 8.3.2. Germany Pediatric Neuroblastoma Treatment Market
- 8.3.3. France Pediatric Neuroblastoma Treatment Market
- 8.3.4. Spain Pediatric Neuroblastoma Treatment Market
- 8.3.5. Italy Pediatric Neuroblastoma Treatment Market
- 8.3.6. Rest of Europe Pediatric Neuroblastoma Treatment Market
- 8.4. Asia-Pacific Pediatric Neuroblastoma Treatment Market Snapshot
- 8.4.1. China Pediatric Neuroblastoma Treatment Market
- 8.4.2. India Pediatric Neuroblastoma Treatment Market
- 8.4.3. Japan Pediatric Neuroblastoma Treatment Market
- 8.4.4. Australia Pediatric Neuroblastoma Treatment Market
- 8.4.5. South Korea Pediatric Neuroblastoma Treatment Market
- 8.4.6. Rest of Asia Pacific Pediatric Neuroblastoma Treatment Market
- 8.5. Latin America Pediatric Neuroblastoma Treatment Market Snapshot
- 8.5.1. Brazil Pediatric Neuroblastoma Treatment Market
- 8.5.2. Mexico Pediatric Neuroblastoma Treatment Market
- 8.6. Rest of The World Pediatric Neuroblastoma Treatment Market
Chapter 9. Competitive Intelligence
- 9.1. Top Market Strategies
- 9.2. Company Profiles
- 9.2.1. United Therapeutics Corporation
- 9.2.1.1. Key Information
- 9.2.1.2. Overview
- 9.2.1.3. Financial (Subject to Data Availability)
- 9.2.1.4. Product Summary
- 9.2.1.5. Recent Developments
- 9.2.2. APEIRON Biologics AG
- 9.2.3. Baxter International
- 9.2.4. Pfizer, Inc.
- 9.2.5. Bayer AG
- 9.2.6. MacroGenics, Inc.
- 9.2.7. Sartorius AG
- 9.2.8. CELLECTAR BIOSCIENCES, INC.
- 9.2.9. PROVECTUS BIOPHARMACEUTICALS, INC.
- 9.2.10. Y-mAbs Therapeutics, Inc.
Chapter 10. Research Process
- 10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
- 10.2. Research Attributes
- 10.3. Research Assumption